Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Pulmatrix, Inc. (PULM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update"
07/13/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine"
06/02/2023 ARS Form ARS - Annual Report to Security Holders:
06/02/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update"
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
02/08/2023 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 2.7% stake in Pulmatrix, Inc.
02/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma"
02/03/2023 8-K Quarterly results
01/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix to Host Key Opinion Leader Webinar “PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment”"
01/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/10/2023 SC 13G/A SABBY MANAGEMENT, LLC reports a 8.3% stake in Pulmatrix, Inc.
01/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Positive Top Line Results from a Phase 1study with PUR3100, a Novel Orally Inhaled Dihydroergotamine , for Acute Migraine PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE"
09/26/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine"
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
08/09/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/12/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
05/02/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/29/2022 8-K Quarterly results
04/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Schedule of Fees"
03/29/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/29/2022 10-K Annual Report for the period ended December 31, 2021
03/29/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update"
03/21/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD"
03/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Regains Compliance With Nasdaq Listing Requirements"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy